The global pharmaceutical CXO market size was estimated at USD 382.6 billion in 2025 and is predicted to increase from USD 416.65 billion in 2026 to approximately USD 897.48 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. The growing adoption of advanced therapies globally is increasing the demand for pharmaceutical CXOs. A rise in the outsourcing trends, R&D investments, clinical trials, technological advancements, and new service launches is also enhancing the market growth.
The pharmaceutical CXO market was driven by a shift towards asset-light business models and an expanding R&D pipeline. The pharmaceutical CXO refers to the companies providing outsourced services to the pharmaceutical, biotechnology, and other healthcare companies. They help in accelerating drug development, offer regulatory compliance, improve scalability, and help in reducing operational costs.
AI is used to accelerate drug discovery by identifying suitable drug candidates, where it also helps in predicting drug success rates. It also helps in detecting deviations and defects, maintaining the quality of the products. AI also offers automation, regulatory compliance, and help in manufacturing and clinical trial optimization.
Expanding Outsourcing Trends
There is a rise in the outsourcing trend among companies due to growing startups and acquisitions to leverage various R&D, manufacturing, and packaging services. Their end-to-end services and shift towards green manufacturing are also attracting the clients.
Growth in Cell & Gene Therapy
Increasing chronic disease burden is driving the demand for cell and gene therapies, enhancing their development. This is leading to collaboration with the pharmaceutical CXO to leverage their wide range of affordable services.
Technological Advancements
Growing technological innovations are promoting the adoption of advanced technologies, which is attracting the client. They accelerate drug development, manufacturing, and clinical trials where their automation helps in reducing manual error.
| Table | Scope |
| Market Size in 2026 | USD 416.65 Billion |
| Projected Market Size in 2035 | USD 897.48 Billion |
| CAGR (2026 - 2035) | 8.9% |
| Leading Region | North America by 39% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Service Type, By Molecule Type, By Drug Development Stage, By Therapeutic Area, By End User, By Scale of Operation, By Region |
| Top Key Players | IQVIA, Catalent, ICON plc, Samsung Biologics, LabCorp, Recipharm, Charles River Laboratories, Thermo Fisher Scientific, Medpace Holding, Lonza Group |
| Segment | Share 2025 (%) |
| Contract Development and Manufacturing Organization (CDMO) | 38% |
| Contract Research Organization (CRO) | 30% |
| Contract Manufacturing Organization (CMO) | 12% |
| Contract Sales Organization (CSO) | 8% |
| Contract Packaging Organization (CPO) | 5% |
| Contract Development Services | 7% |
The Contract Development and Manufacturing Organization (CDMO) Segment Dominated the Market With 38% in 2025
The contract development and manufacturing organization (CDMO) segment led the pharmaceutical CXO market with 38% share in 2025, driven by growth in outsourcing manufacturing to reduce operational costs and improve scalability. Growth in the biologics pipelines also enhanced the demand for specialized production facilities. Expansion of flexible manufacturing capacities also supported their long-term outsourcing contracts.
The contract research organization (CRO) segment held the second-largest share of 30% of the market in 2025, due to rising clinical trial complexity, which is driving the outsourcing of research activities. Their faster patient recruitment and regulatory expertise are also increasing their use. AI-enabled trial management is also driving its adoption.
The contract manufacturing organization (CMO) segment held 12% of the pharmaceutical CXO market share in 2025, due to increasing demand for cost-efficient commercial manufacturing. Growing generic drug production and sterile manufacturing investments also drive their use. Pharmaceutical firms focusing on core competencies also increase their use.
The contract development services segment held 7% of the market share in 2025 and is expected to witness the fastest growth with a CAGR of 10.8% during the forecast period, due to growing complex biologics and personalized therapies. Rapid scale-up and technology transfer services are also increasing in demand. Accelerated development timelines are increasing their use.
| Segment | Share 2025 (%) |
| Small Molecules | 52% |
| Biologics | 31% |
| Cell & Gene Therapy | 10% |
| Oligonucleotides & Peptides | 7% |
The Small Molecules Segment Dominated the Market With 52% in 2025
The small molecules segment accounted for the highest revenue share of 52% of the pharmaceutical CXO market in 2025, due to the growth in their approved drug pipelines globally. Established manufacturing infrastructure also supported their large-scale outsourcing. Generic drug expansion also sustained their long-term production demand.
The biologics segment held the second-largest share of 31% of the market in 2025, due to growing demand for specialized biologics manufacturing. Monoclonal antibody commercialization also continues to expand the use of pharmaceutical CXO services. Cold-chain logistics and high-value therapeutics also favor outsourcing partnerships.
The cell & gene therapy segment held 10% of the pharmaceutical CXO market share in 2025 and is expected to show the highest growth during the forecast period, driven by growing demand for personalized medicine. Limited in-house expertise also drives partnerships with advanced CXO providers. Regulatory approvals for novel therapies are increasing manufacturing investments, promoting their use.
The oligonucleotides & peptides segment held 7% of the market share in 2025, driven by RNA therapeutics and peptide drugs, which are gaining clinical traction. Advanced synthesis technologies improve scalability and purity, driving the demand for pharmaceutical CXO services. Pharmaceutical firms are also outsourcing specialized production capabilities.
| Segment | Share 2025 (%) |
| Discovery Stage | 16% |
| Preclinical Stage | 21% |
| Clinical Stage | 37% |
| Commercial Manufacturing Stage | 26% |
The Clinical Stage Segment Dominated the Market With 37% in 2025
The clinical stage segment held a major revenue share of 37% of the pharmaceutical CXO market in 2025, and is expected to expand rapidly with a CAGR of 9.40% during the forecast period, driven by growth in pharmaceutical companies outsourcing target identification and screening. AI-driven drug discovery platforms also improved their efficiency. Virtual biotech models also expanded early-stage partnerships.
The commercial manufacturing stage segment held the second-largest share of 26% of the market in 2025, due to rising biologics commercialization. Pharmaceutical firms seek supply chain flexibility and cost optimization, promoting their use. Their continuous manufacturing technologies are also improving productivity and compliance.
The preclinical stage segment held 21% of the pharmaceutical CXO market share in 2025, due to growing demand for toxicology and bioanalytical testing. Regulatory compliance requirements also support outsourcing growth. Preclinical service providers also offer specialized infrastructure and expertise, which increases their use.
The discovery stage segment held 16% of the market share in 2025, as pharmaceutical companies increasingly outsource target identification and screening. AI-driven drug discovery platforms also offer improved efficiency. Virtual biotech models are expanding early-stage partnerships.
| Segment | Share 2025 (%) |
| Oncology | 28% |
| Cardiovascular Diseases | 12% |
| Neurology | 10% |
| Infectious Diseases | 11% |
| Metabolic Disorders | 9% |
| Respiratory Diseases | 7% |
| Rare Diseases | 8% |
| Immunology & Autoimmune Disorders | 10% |
| Others | 5% |
The Oncology Segment Dominated the Market With 28% in 2025
The oncology segment contributed the biggest revenue share of 28% of the pharmaceutical CXO market in 2025 and is expected to gain the highest share with a CAGR of 11.5% during the forecast period, due to rapid oncology drug approvals. Precision medicine and biologics development also required specialized capabilities. Growth in clinical trial activities has also increased the use of pharmaceutical CXO services.
The cardiovascular diseases segment held the second-largest share of 12% of the market in 2025, due to the growing chronic disease burden. Generic cardiovascular drug manufacturing also remains highly outsourced. Emerging therapies are increasing clinical research investments, promoting the use of pharmaceutical CXO services.
The infectious diseases segment held 11% of the pharmaceutical CXO market share in 2025, due to expanding vaccine development and antiviral research. Governments support pandemic preparedness investments, which also drives the demand for pharmaceutical CXO services. Biomanufacturing partnerships also strengthen production scalability.
The neurology segment held 10% of the market share in 2025, driven by the rising prevalence of neurodegenerative diseases, which supports R&D expansion. CNS drug development complexity also drives CRO utilization. Advanced biomarker discoveries also increase their use to improve neurological clinical trial success rates.
| Segment | Share 2025 (%) |
| Pharmaceutical Companies | 54% |
| Biotechnology Companies | 31% |
| Academic & Research Institutes | 9% |
| Government Organizations | 6% |
The Pharmaceutical Companies Segment Dominated the Market With 54% in 2025
The pharmaceutical companies segment held the largest revenue share of 54% of the pharmaceutical CXO market in 2025, as large pharmaceutical firms adopted asset-light business models. Outsourcing improved operational flexibility and cost efficiency. Expansion of the drug pipelines also sustained long-term CXO partnerships.
The biotechnology companies segment held the second-largest share of 31% of the market in 2025 and is expected to grow with the fastest CAGR of 11.8% during the forecast period, due to emerging biotech firms relying heavily on external development capabilities. Venture-backed innovation also drives demand for integrated CXO services. Specialized biologics development also increases outsourcing penetration.
The academic & research institutes segment held 9% of the pharmaceutical CXO market share in 2025, due to expanding translational research activities. Academic collaborations also support early-stage therapeutic innovation. Limited in-house commercialization expertise also increases outsourcing demand.
The government organizations segment held 6% of the market share in 2025, due to growing public health initiatives supporting vaccine and biologics manufacturing. Government-funded clinical programs require external operational support, which increases pharmaceutical CXO services use. Strategic domestic manufacturing investments also promote their use.
North America dominated the pharmaceutical CXO market with 39% in 2025, due to strong pharmaceutical R&D spending, which supported extensive outsourcing activity. Advanced biologics manufacturing infrastructure also promoted the use of pharmaceutical CXO services. The presence of major CRO and CDMO providers also accelerated the market growth.
U.S. Market Trends
Presence of leading pharmaceutical innovators in the U.S. sustains outsourcing demand. Advanced biologics and clinical trial infrastructure also support its market leadership. A strong FDA-regulated manufacturing ecosystem also attracts investments, promoting its use.
Asia Pacific held 25% share of the pharmaceutical CXO market in 2025 and is expected to grow at the fastest CAGR of 11.7% during the forecast period, due to lower operational costs attracting pharmaceutical outsourcing contracts globally. Expansion of the large-scale manufacturing infrastructure across China and India is also enhancing their growth. Government incentives supporting biotechnology and increasing clinical research are also enhancing the market growth.
China Market Trends
The presence of large-scale manufacturing infrastructure in China supports global outsourcing demand. Expanding domestic biopharmaceutical innovation also drives the adoption of pharmaceutical CXO services. Regulatory reforms also improve international collaboration opportunities.
R&D
Clinical Trials and Regulatory Approvals
Patient Support and Services
| Companies | Headquarters | Services |
| IQVIA | Durham, U.S. | Clinical data and trial management |
| Catalent | Somerset, U.S. | Advanced drug delivery technology manufacturing |
| ICON plc | Dublin, Ireland | Phase I-IV drug development and decentralized trial tech |
| Samsung Biologics | Incheon, South Korea | High-capacity monoclonal antibody manufacturing |
| Labcorp | Burlington, U.S. | Preclinical, clinical trial testing, and the central laboratory |
| Recipharm | Stockholm, Sweden | Inhalation devices and sterile injectable development |
| Charles River Laboratories | Wilmington, U.S. | Early-stage drug discovery and analytical testing |
| Thermo Fisher Scientific | Waltham, U.S. | Clinical trial |
| Medpace Holding | Cincinnati, U.S. | Full-service clinical trials |
| Lonza Group | Basel, Switzerland | Biologics and cell & gene therapy manufacturing |
Strengths
Weaknesses
Opportunities
Threats
By Service Type
By Molecule Type
By Drug Development Stage
By Therapeutic Area
By End User
By Scale of Operation
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
